HTI was formed in 2004 as a majority-owned portfolio company of Cato BioVentures. Through its strategic development relationship with Cato BioVentures and its contract research and development affiliate, Cato Research Ltd., HTI is executing its phase 2 development program for HTI-101, a novel small molecule combination therapy for obesity-related hypertension (ORH), one of the world’s fastest growing cardiovascular disease markets.
